Search results
Brevan Howard Capital Management LP Makes New $1.97 Million Investment in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 7 hours agoBrevan Howard Capital Management LP purchased a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) in the fourth quarter, Holdings Channel reports. The fund purchased ...
AbbVie and FutureGen link on inflammatory bowel disease
Pharmaceutical Technology via Yahoo Finance· 4 hours agoAbbVie has made a licence agreement with FutureGen Biopharmaceutical to develop a next-generation...
Here's How Many Shares Of AbbVie You Would Need To Earn $500 Per Month In Dividends
Benzinga via Yahoo Finance· 20 hours agoWith 52 consecutive years of dividend growth and a dividend yield of over 3.6%, AbbVie Inc....
AbbVie inks immune disorder drug licensing deal with China's FutureGen
Reuters via AOL· 22 hours agoAbbVie has been counting on its newer immunology medicines to help make up for declining sales of...
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks via Yahoo Finance· 2 days agoAbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want...
AbbVie Signs On To Recruit Diverse Talent at Upcoming HBCU Connect Annual Conference & Career Fair...
BlackNews.com· 8 hours agoOn Friday, June 28th, 2024 at Washington Nationals Stadium in Washington, DC, HBCU CONNECT will host...
AbbVie inks deal potentially worth $1.7 billion for new IBD drug
Crain s Chicago Business· 21 hours agoAbbVie's latest move in inflammatory bowel disease treatments is a licensing agreement to develop a next generation antibody engineered by Beijing-based FutureGen. The terms ...
AbbVie joins TL1A race via $150M upfront deal with China's FutureGen
FierceBiotech· 22 hours agoAbbVie has become the latest Big Pharma to jump on the anti-TL1A train, paying China’s FutureGen Biopharmaceutical $150 million upfront for a preclinical inflammatory bowel ...
Heads Up: Abbvie's Migraine Portfolio 'Very, Very Strong'
MediaPost· 1 day agoIn the wake of Abbvie’s loss of exclusivity for its blockbuster Humira anti-inflammatory drug, its migraine-fighting meds -- Ubrelva, Qulipta and Botox -- have emerged as ...
AbbVie Inc. (NYSE:ABBV) Holdings Lowered by Westwood Holdings Group Inc.
ETF DAILY NEWS· 4 days agoWestwood Holdings Group Inc. lessened its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 0.6% during the fourth quarter, Holdings Channel.com reports. The fund ...